Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-14

Clinical Trial Update: SCI-110 for Alzheimer Disease and Agitation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SCI-110 in Alzheimer disease and agitation is in early stages with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SCI-110

Snippet

Sponsor: The Israeli Medical Center for Alzheimer's | Conditions: Alzheimer Disease | Phase 2 | Status: UNKNOWN